Increased Arbekacin Clearance in Patients With Febrile Neutropenia.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
20
7
2019
medline:
29
4
2021
entrez:
20
7
2019
Statut:
ppublish
Résumé
Arbekacin (ABK) is used to treat infections caused by methicillin-resistant Staphylococcus aureus and is used widely for the treatment of febrile neutropenia (FN). As ABK has a narrow therapeutic concentration window, the dosage must be adjusted via therapeutic drug monitoring. However, the influence of the physiology of patients with FN on the pharmacokinetic (PK) parameters of ABK remains unclear. Therefore, we examined this influence on ABK PK parameters. We performed a retrospective cohort study using data from patients with a hematologic malignancy who were ≥18 years and had been administered ABK. We excluded patients who did not receive therapeutic drug monitoring and had an estimated glomerular filtration rate (eGFR) of <30 mL/min, because clinically sufficient data would not be available. Of the 99 enrolled patients, 25 did not have FN and 74 had FN. Arbekacin clearance (CLabk) was shown to correlate with eGFR in patients with FN (r = 0.32, P = 0.0062) and without FN (r = 0.50, P = 0.01). CLabk was higher in patients with FN than in those without FN. In addition, in the eGFR of <100 mL/min group (normal renal function), CLabk and CLabk/eGFR were also higher in patients with FN than in those without FN. CLabk was increased in patients with FN and normal renal function; therefore, we propose an increased ABK dose for patients with FN and normal renal function.
Sections du résumé
BACKGROUND
Arbekacin (ABK) is used to treat infections caused by methicillin-resistant Staphylococcus aureus and is used widely for the treatment of febrile neutropenia (FN). As ABK has a narrow therapeutic concentration window, the dosage must be adjusted via therapeutic drug monitoring. However, the influence of the physiology of patients with FN on the pharmacokinetic (PK) parameters of ABK remains unclear. Therefore, we examined this influence on ABK PK parameters.
METHOD
We performed a retrospective cohort study using data from patients with a hematologic malignancy who were ≥18 years and had been administered ABK. We excluded patients who did not receive therapeutic drug monitoring and had an estimated glomerular filtration rate (eGFR) of <30 mL/min, because clinically sufficient data would not be available.
RESULT
Of the 99 enrolled patients, 25 did not have FN and 74 had FN. Arbekacin clearance (CLabk) was shown to correlate with eGFR in patients with FN (r = 0.32, P = 0.0062) and without FN (r = 0.50, P = 0.01). CLabk was higher in patients with FN than in those without FN. In addition, in the eGFR of <100 mL/min group (normal renal function), CLabk and CLabk/eGFR were also higher in patients with FN than in those without FN.
CONCLUSIONS
CLabk was increased in patients with FN and normal renal function; therefore, we propose an increased ABK dose for patients with FN and normal renal function.
Identifiants
pubmed: 31323015
doi: 10.1097/FTD.0000000000000678
pii: 00007691-202002000-00016
doi:
Substances chimiques
Anti-Infective Agents
0
Dibekacin
45ZFO9E525
arbekacin
G7V6SLI20L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-138Références
Freifeld AG, Bow EJ, Sepkowitz KA, et al.; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–e93.
Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58:3799–3803.
Hwang JH, Lee JH, Moon MK, et al. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis. 2012;31:1663–1666.
Miura K, Nakagawa M, Takahashi H, et al. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies. Int J Hematol. 2016;103:334–340.
Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative pathogens. Clin Pharmacol. 2014;6:139–148.
Okada K, Kimura T, Mikamo H, et al.; Japanese Society of Chemotherapy and Japanese Society of Therapeutic Drug Monitoring. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of therapeutic drug monitoring. J Infect Chemother. 2014;20:1–5.
Otsuka T, Tanaka A, Suemaru K, et al. Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin. J Clin Pharm Ther. 2008;33:227–235.
Blot S, Lipman J, Roberts DM, et al. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. Diagn Microbiol Infect Dis. 2014;79:77–84.
Hirai K, Ishii H, Shimoshikiryo T, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. Ther Drug Monit. 2016;38:706–710.
Zeitany RG, El Saghir NS, Santhosh-Kumar CR, et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother. 1990;34:702–708.
Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(suppl 1):S49–S52.
Matsuo S, Imai E, Horio M, et al.; Collaborators Developing the Japanese Equation for Estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.
Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183–195.
Denaro CP, Ravenscroft PJ. Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients. Br J Clin Pharmacol. 1989;28:37–44.
Shimamoto Y, Fukuda T, Tominari S, et al. Decreased vancomycin clearance in patients with congestive heart failure. Eur J Clin Pharmacol. 2013;69:449–457.
Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(suppl 1):S32–S37.
Fukuoka N, Aibiki M. Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance. J Clin Pharm Ther. 2008;33:521–527.
Kim JH, Lah HO, Yim DS. Population pharmacokinetics of arbekacin in burn patients. Eur J Clin Pharmacol. 2008;64:599–603.
Tanigawara Y, Sato R, Morita K, et al. Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:3754–3762.